Foscan® uptake and tissue distribution in relation to photodynamic efficacy

British Journal of Cancer

Volumn 88, Issue 2, 2003, Pages 283-290

  Cramers, P ^a   Ruevekamp, M ^a   Oppelaar, H ^a   Dalesio, O ^a   Baas, P ^a   Stewart, F A ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Foscan; Pharmacokinetics; Photodynamic therapy; Vascular damage

Indexed keywords

TEMOPORFIN; CARBON; MESOPORPHYRIN; PHOTOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOCIATION; DRUG BLOOD LEVEL; DRUG UPTAKE; FEMALE; LIGHT; MESOTHELIOMA; MOUSE; NONHUMAN; NUDE MOUSE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; STEADY STATE; TIME; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HUMAN; METABOLISM; PATHOLOGY; PHOTOCHEMOTHERAPY;

ANIMALS; CARBON ISOTOPES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LIGHT; MESOPORPHYRINS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TISSUE DISTRIBUTION;

EID: 0037467570     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600682     Document Type: Article

References (27)

1. Alian W, Andersson-Engels S, Svanberg K, Svanberg S (1994) Laser-induced fluorescence studies of meso-tetra(hydroxyphenyl)chlorin in malignant and normal tissues in rats. Br J Cancer 70: 880 - 885
2. Andrejevic Blant S, Grosjean P, Ballini JP, Wagnieres G, Van den Bergh H, Fontolliet C, Monnier P (2001) Localization of tetra(m-hydroxyphenyl)chlorin (Foscan) in human healthy tissues and squamous cell carcinomas of the upper aero-digestive tract, the esophagus and the bronchi: a fluorescence microscopy study. J Photochem Photobiol B 61: 1 - 9
3. Andrejevic-Blant S, Hadjur Ch, Ballini J-P, Wagnieres G, Fontolliet C, Van den Bergh H, Monnier P (1997) Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug - light interval. Br J Cancer 76: 1021 - 1028
4. Baas P, Saarnak AE, Oppelaar H, Neering H, Stewart FA (2001) Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study. Br J Dermatol 145: 75 - 78
5. Braichotte D, Savary JF, Glanzmann T, Westermann P, Folli S, Wagnieres G, Monnier P, van den BH (1995) Clinical pharmacokinetic studies of tetra(meta-hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengths. Int J Cancer 63: 198 - 204
6. Braichotte D, Wagnieres G, Philippoz JM, Ris HB, Van den Bergh H (1992) Preliminary clinical results on a second generation photosensitizer: mTHPC. In Photodynamic Therapy and Biomedical Lasers, Spinelli P, Dal Fante M, Marchesini R (eds) pp 461 - 465. Amsterdam: Elsevier Science Publishers B.V.
7. Dilkes MG, DeJode ML, Rowntree-Taylor A, McGilligan JA, Kenyon GS, McKelvie P (1996) m-THPC photodynamic therapy for head and neck cancer. Lasers Med Sci 11: 23 - 29
8. Fan K, Hopper C, Speight P, Bionaccorsie G, Bown S (1997) Photodynamic therapy using mTHPC for malignant disease in the oral cavity. Int J Cancer 73: 25 - 32
9. Fingar VH, Wieman TJ, Weber Doak K (1990) Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. Cancer Res 50: 2599 - 2604
10. Fingar VH, Wieman TJ, Wiehl SA (1992) The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res 52: 4914 - 4921
11. Glanzmann T, Hadjur C, Zellweger M, Grosiean P, Forrer M, Ballini JP, Monnier P, Van den Bergh H, Lim CK, Wagnieres G (1998) Pharmacokinetics of tetra(m-hydroxyphenyl)chlorin in human plasma and individualized light dosimetry in photodynamic therapy. Photochem Photobiol 67: 596 - 602
12. Gomer CJ, Dougherty TJ (1979) Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res 39: 146 - 151
13. Grosjean P, Savary JF (1996) Tetra-(mTHPC) clinical PDT. Lasers Med Sci 11: 227 - 235
14. Henderson BW, Waldow SM, Mang TS, Potter WR, Malone PB, Dougherty TJ (1985) Tumour destruction and kinetics of tumour cell death in two experimental mouse tumours folowing photodynamic therapy. Cancer Res 45: 572 - 576
15. Hopkinson HJ, Vernon DI, Brown SB (1999) Identification and partial characterization of an unusual distribution of the photosensitizer meta-tetrahydroxyphenyl chlorin (temoporfin) in human plasma. Photochem Photobiol 69: 482 - 488
16. Morlet L, Vonarx-Coinsmann V, Lenz P, Foultier M-T, De Brito LX, Stewart CM, Patrice T (1995) Correlation between meta(tetrahydroxyphenyl)chlorin (m-THPC) biodistribution and photodynamic effects in mice. Photochem Photobiol 28: 25 - 32
17. Peng Q, Moan J, Ma LW, Nesland JM (1995) Uptake, localization, and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma. Cancer Res 55: 2620 - 2626
18. Ris HB, Altermatt HJ, Inderbitzi R, Hess R, Nachbur B, Stewart JC, Wang Q, Lim CK, Bonnett R, Berenbaum MC (1991) Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer 64: 1116 - 1120
19. Ris HB, Altermatt HJ, Nachbur B, Stewart JCM, Wang Q, Lim CK, Bonnett R, Althaus U (1993) Effect of drug - light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma. Int J Cancer 53: 141 - 146
20. Savary JF, Monnier P, Fontolliet C, Mizeret J, Wagnieres G, Braichotte D, Van den Bergh H (1997) Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin. Arch Otolaryngol Head Neck Surg 123: 162 - 168
21. Star WM, Marijnissen HPA, Van den Berg-Blok AE, Versteeg JAC Franken KAP, Reinhold HS (1986) Destruction of rat mammary tumour and normal tissue microcirculation by hematoporphyrin derivative photo-irradiation obderved in vivo in sandwich observation chambers. Cancer Res 46: 2532 - 2540
22. Van Geel IPJ, Oppelaar H, Oussoren YG, Schuitmaker JJ, Stewart FA (1995) Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C. Br J Cancer 72: 344 - 350
23. Veenhuizen R, Oppelaar H, Ruevekamp M, Schellens J, Dalesio O, Stewart F (1997a) Does tumour uptake of Foscan determine PDT efficacy? Int J Cancer 73: 236 - 239
24. Veenhuizen RB, Ruevekamp MC, Oppelaar H, Helmerhorst TJ, Kenemans P, Stewart FA (1997b) Foscan-mediated photodynamic therapy for a peritoneal-cancer model: drug distribution and efficacy studies. Int J Cancer 73: 230 - 235
25. Whelpton R, Michael-Titus AT, Basra SS, Grahn M (1995) Distribution of temoporfin, a new photosensitizer for the photodynamic therapy of cancer, in a murine tumor model. Photochem Photobiol 61: 397 - 401
26. Whelpton R, Michael-Titus AT, Jamdar RP, Abdillahi K, Grahn MF (1996) Distribution and excretion of radiolabeled temoporfin in a murine tumor model. Photochem Photobiol 63: 885 - 891
27. Wierrani F, Fiedler D, Grin W, Henry M, Krammer B, Grunberger W (1997) Intraoperative meso-tetrahydroxyphenylchlorin-based photodynamic therapy in metastatic gynecologic cancer tissue: initial results. J Gynecol Surg 13: 23 - 29